Ralf Kuriyel, Senior VP, R&D at REPLIGEN CORP (RGEN), sold 15,905 shares at $126.88 ($2.0M) on 2020-05-13, disclosed to the SEC on 2020-05-15.
Open-market sale of $2.0M RGEN by Senior VP, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $126.88 | 1,612 | $205K | 10.1% |
| 2 | $126.88 | 1,612 | $205K | 10.1% |
| 3 | $128.02 | 6,293 | $806K | 39.6% |
| 4 | $128.02 | 6,293 | $806K | 39.6% |
| 5 | $128.55 | 95 | $12K | 0.6% |
| Total | $127.79 avg | 15,905 |
| $2.0M |
| 100% |
| Filing → |
| RGEN | SELL | 2024-03-12 | $1.4M | — | Filing → |
| RGEN | SELL | 2022-08-12 | $2.3M | — | Filing → |
| RGEN | SELL | 2021-09-02 | $2.3M | — | Filing → |